Compare RVSB & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | INO |
|---|---|---|
| Founded | 1923 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 100.4M |
| IPO Year | 1997 | 1999 |
| Metric | RVSB | INO |
|---|---|---|
| Price | $5.27 | $1.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.00 | $6.75 |
| AVG Volume (30 Days) | 200.8K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | $53.63 | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $4.74 | $1.03 |
| 52 Week High | $6.22 | $2.86 |
| Indicator | RVSB | INO |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 51.80 |
| Support Level | $5.24 | $1.03 |
| Resistance Level | $5.47 | $1.24 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 10.22 | 53.85 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.